fda remove semaglutide from shortage list Novo's Wegovy and Ozempic removed US list, compounders on notice Semaglutide and Tirzepatide off FDA

doi: 10.1097/MPA.0000000000000521 79 ElashoffMMatveyenkoAVGierBElashoffRButlerPC

The aim of the Biosecure Act is to stop biotechs and manufacturers in China from collaborating with US pharma companies or receiving any US funding, citing security risks funding would include payments for medicines made there from government sources, including Medicare and Medicaid

They may adjust your medication, order further testing, or provide additional treatment options

FSA and HSA funds may be eligible for Trimi's program per brand disclosure - confirm eligibility with your specific FSA/HSA administrator before assuming reimbursement

Initiation rates for AOM GLP-1 RA increased substantially in March 2024, relative to December 2023 (+41.41%)